troglitazone has been researched along with Thrombosis in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Type 2 diabetes mellitus is associated with accelerated atherosclerosis and a high rate of arterial thrombotic complications." | 2.70 | Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control. ( Badimon, JJ; Crandall, JP; Fallon, JT; Fuster, V; Heflt, G; Herson, P; Lev, EI; Osende, JI; Rabito, P; Rauch, U; Rodriguez, OJ; Vidhun, R; Zaman, A, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Osende, JI | 1 |
| Badimon, JJ | 1 |
| Fuster, V | 1 |
| Herson, P | 1 |
| Rabito, P | 1 |
| Vidhun, R | 1 |
| Zaman, A | 1 |
| Rodriguez, OJ | 1 |
| Lev, EI | 1 |
| Rauch, U | 1 |
| Heflt, G | 1 |
| Fallon, JT | 1 |
| Crandall, JP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Assessment of Platelet-dependent Thrombosis in Patients With Acute Coronary Syndromes Using an ex Vivo Arterial Injury Model[NCT00728286] | 90 participants (Actual) | Observational | 2008-10-31 | Completed | |||
| Assessment of Platelet-dependent Thrombosis by an ex Vivo Arterial Injury Model: a Placebo Controlled Trial of Clopidogrel as Antiplatelet Therapy in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease[NCT00728156] | Phase 4 | 90 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for troglitazone and Thrombosis
| Article | Year |
|---|---|
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control.
Topics: Analysis of Variance; Arteriosclerosis; Blood Coagulation; Blood Coagulation Tests; Chromans; Combin | 2001 |
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control.
Topics: Analysis of Variance; Arteriosclerosis; Blood Coagulation; Blood Coagulation Tests; Chromans; Combin | 2001 |
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control.
Topics: Analysis of Variance; Arteriosclerosis; Blood Coagulation; Blood Coagulation Tests; Chromans; Combin | 2001 |
Blood thrombogenicity in type 2 diabetes mellitus patients is associated with glycemic control.
Topics: Analysis of Variance; Arteriosclerosis; Blood Coagulation; Blood Coagulation Tests; Chromans; Combin | 2001 |